# Sunitinib Malate in Treating Patients With Kidney Cancer

> **NCT00943839** · NA · COMPLETED · sponsor: **Centre Antoine Lacassagne** · enrollment: 60 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** sunitinib malate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00943839
- **Lead sponsor:** Centre Antoine Lacassagne
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943839, "Sunitinib Malate in Treating Patients With Kidney Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00943839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*